FOSRENOL (R) maintains bone health status of end-stage renal disease patients
ST. LOUIS, Mo. Oct. 29, 2004 - Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announces that long-term treatment with FOSRENOL (lanthanum carbonate), a new non-calcium, non-aluminum phosphate binder, does not promote bone softening or cause harmful effects on bone, according to data presented today at the American Society of Nephrology (ASN) annual meeting in St. Louis,...FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
Basingstoke, UK, 27 October 2004 The U.S. Food and Drug Administration (FDA) today approved FOSRENOL (lanthanum carbonate), a new non-calcium, non-aluminium phosphate binder that reduces high serum phosphate levels in patients with end-stage renal disease (ESRD)....... Without effective treatment, this condition often leads to renal osteodystrophy, a collection of bone diseases that causes bo...New global trials help to make FOSRENOL(R) the most extensively studied modern phosphate binder
The new studies which will focus on reaching target serum phosphate levels as defined by the K/DOQI guidelines (Kidney Disease Outcomes Quality initiative) will strengthen FOSRENOL's position as the most extensively studied modern phosphate binder....... Congress in Lisbon, which demonstrated that patients with end stage renal disease (ESRD) treated with FOSRENOL can largely avoid the damagin...First global approval for FOSRENOL (lanthanum carbonate)
Basingstoke, UK 24 March 2004 - Sweden's MPA has today granted the first regulatory approval in the world for FOSRENOL (lanthanum carbonate), a non-calcium, non-aluminium phosphate binding medicine developed to control phosphate levels in renal dialysis patients. Sweden will now become the Reference Member State in the EU Mutual Recognition Procedure for FOSRENOL, and this is the first step in s...Fosrenol shows significant reduction in serum phosphate in Chinese end-stage kidney disease patients
Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced that treatment with FOSRENOL (lanthanum carbonate) significantly reduced and maintained phosphate levels in a study of Chinese end-stage renal disease (ESRD) patients with hyperphosphatemia, according to data presented at the American Society of Nephrology (ASN) 36th Annual Meeting.... ...The 11-week study, present...